PATENT CLAIM ANALYSIS

Application Number: 15895877
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "021500"]

Abstract:
The present invention provides for novel peptide inhibitors and methods for treating polyglutamine (polyQ) diseases. Also disclosed are related compositions and kits for therapeutic use in the treatment of polyQ diseases.

Claim (Index 25):
The use of  claim 24 , wherein the polypeptide consists of SEQ ID NO:1 with N-terminal acetylation and C-terminal amidation, optionally further comprising N-terminal lipidation by N-acylation with palmitic acid.

Metadata:
- Claim Count in Document: 30.0
- Percentile: 88.0
- Lexical Diversity: 1.2069
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14293816', '15455809', '15382380', '14555316', '13766659']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7526776913827682
- 35 USC 102 Novelty (BERT): 0.5174643378132256
- Combined Prediction Score: 0.729156356025814
- Mean Citation Score: 267.69647000000003
- Max Citation Score: 307.73114
- Similarity Product: 214.9867687506712

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test